Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson’s disease center
Objective: To describe the frequency, characteristics and potential risk factors for Dopamine Agonist Withdrawal Syndrome (DAWS). Background: Dopamine agonists are a mainstay of treatment for…Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson’s disease patients: Dosing patterns
Objective: Describe the dosing patterns in advanced Parkinson's disease (PD) patients who completed conversion to IPX066 from other levodopa formulations. Background: IPX066 is an extended-release…Critical path for Parkinson’s II: Global regulatory agencies support the use of dopamine transporter neuroimaging as an enrichment biomarker to enable clinical trials in early Parkinson’s disease
Objective: This presentation focuses on neuroimaging of the Dopamine Transporter as an enrichment biomarker in clinical trials of Parkinson's disease (PD). Background: The Critical Path…Conversion of patients from immediate release carbidopa-levodopa (IR CD-LD) and sustained release carbidopa-levodopa (SR CD-LD) to extended-release carbidopa-levodopa (ER CD-LD) in clinical practice
Objective: To evaluate the real-world response of patients who are converted from IR CD-LD and SR CD-LD to ER CD-LD in an academic practice. Background:…Lessons-experienced in the creation of a global public-private consortium with the goal of advancing treatments that hold most potential for delayed disease progression in Parkinson’s disease – Critical path for Parkinson’s (CPP)
Objective: The path is summarized that led to the creation of a global public-private-partnership uniting an international non-profit charity, Parkinson's UK, a global non-profit organization,…Extended-release carbidopa-levodopa, IPX066: Dosing and efficacy with concomitant medication use in Parkinson’s disease
Objective: Evaluate the efficacy and dosing of IPX066 in patient groups taking concomitant Parkinson's disease (PD) medication, using post hoc subgroup analyses. Background: IPX066 is…The dopamine agonist withdrawal syndrome rating scale (DAWS-RS): Initial development of a new non-motor scale
Objective: To describe the development of the dopamine agonist withdrawal syndrome (DAWS) rating scale (DAWS-RS), a new questionnaire designed to evaluate the symptoms, severity, and…Reflex saccades changes can estimate long-term symptom progression in DBS STN and MED Parkinson’s disease patients (PD)
Objective: The aim of this study was to evaluate the impact of STN DBS on RS parameters in PD. We have compared disease progression in…Long-term effects of levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease patients: Dutch multicenter retrospective cohort study
Objective: To determine the long-term outcomes of levodopa/carbidopa intestinal gel infusion (LCIG) in advanced Parkinson's disease (PD) patients. Background: LCIG was introduced in the Netherlands…The impact of STN DBS on kinetic tremor in Parkinson’s disease patients
Objective: The aim of the study is to evaluate the impact of STN DBS on kinetic tremor in PD patients in comparison to pharmacologically treated…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.